Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.

about

Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.

Item

http://www.wikidata.org/entity/Q50128334

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Real world treatment patterns ...... integrated healthcare system.

@en

Real world treatment patterns ...... integrated healthcare system.

@nl

type

Item

label

Real world treatment patterns ...... integrated healthcare system.

@en

Real world treatment patterns ...... integrated healthcare system.

@nl

prefLabel

Real world treatment patterns ...... integrated healthcare system.

@en

Real world treatment patterns ...... integrated healthcare system.

@nl

P1476

Real world treatment patterns ...... integrated healthcare system.

@en

P2093

Brian Stwalley

http://www.w3.org/2001/XMLSchema#string

Eugene Felber

http://www.w3.org/2001/XMLSchema#string

Han A Koh

http://www.w3.org/2001/XMLSchema#string

Kathy J Lin

http://www.w3.org/2001/XMLSchema#string

Nazia Rashid

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

Race and ethnicity data quality and imputation using U.S. Census data in an integrated health system: the Kaiser Permanente Southern California experience.

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.

The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.

P304

1078155217697484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217697484

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29284347

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia